Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Ad-PR vaccine
- Development stage
- Preclinical
- Lead developer
- Duke University
- Modality
- Gene Therapies, Vaccines & Immunotherapeutics
- Administration
- Intradermal, Subcutaneous
01
Overview
The Ad-PR vaccine is a preclinical, first-generation adenoviral vector-based cancer vaccine encoding the progesterone receptor (PR), specifically isoforms PR-A and PR-B. Developed by researchers at Duke University and the University of Kansas, the vaccine is designed to immunologically target hormone receptor-positive (HR+) breast cancer. Progesterone receptor signaling has been shown to play an immunosuppressive role in the tumor microenvironment of HR+ breast cancers, contributing to resistance against endocrine inhibition therapy. By delivering codon-optimized human or mouse PR sequences via an adenoviral vector, the vaccine elicits PR-specific T-cell responses (specifically CD8+ cytotoxic T cells) to overcome local immunosuppression and target PR-expressing tumor cells.
- Other names
- PR vaccineadenoviral progesterone receptor vaccineadenovirus-based progesterone receptor vaccineprogesterone receptor vaccine
02
Targets
PR (Progesterone receptor)
Beyond the preview
Go deeper on Ad-PR vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Ad-PR vaccine.